Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ – Get Free Report) passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $2.24 and traded as low as $2.21. Creative Medical Technology shares last traded at $2.23, with a volume of 96,464 shares traded.
Analysts Set New Price Targets
Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Creative Medical Technology in a research report on Friday, May 22nd. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Reduce”.
View Our Latest Stock Analysis on Creative Medical Technology
Creative Medical Technology Stock Performance
Creative Medical Technology (NASDAQ:CELZ – Get Free Report) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.01. Analysts expect that Creative Medical Technology Holdings, Inc. will post -1.57 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Creative Medical Technology
An institutional investor recently bought a new position in Creative Medical Technology stock. Jane Street Group LLC bought a new stake in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned about 1.17% of Creative Medical Technology at the end of the most recent quarter. 1.42% of the stock is currently owned by institutional investors and hedge funds.
Creative Medical Technology Company Profile
Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.
The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.
Read More
- Five stocks we like better than Creative Medical Technology
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Receive News & Ratings for Creative Medical Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Creative Medical Technology and related companies with MarketBeat.com's FREE daily email newsletter.
